Dynamics of Prolyl Hydroxylases Levels During Disease Progression in Experimental Colitis

• Published in: Inflammation Vol. 42; no. 6; pp. 2032 - 2036
• Main Authors: Bakshi, Hamid A., Mishra, Vijay, Satija, Saurabh, Mehta, Meenu, Hakkim, Faruk L., Kesharwani, Prashant, Dua, Kamal, Chellappan, Dinesh K., Charbe, Nitin B., Shrivastava, Garima, Rajeshkumar, S., Aljabali, Alaa A., Al-Trad, Bahaa, Pabreja, Kavita, Tambuwala, Murtaza M.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.12.2019; Springer Nature B.V
• Subjects: Animals; Biomedical and Life Sciences; Biomedicine; Colitis; Colitis - drug therapy; Colitis - enzymology; Colitis - pathology; Colon; Disease Progression; Hypoxia; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunology; Inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory Bowel Diseases - drug therapy; Internal Medicine; Intestine; Isoforms; Mice; Original; Original Article; Pathology; Pharmacology/Toxicology; Prolyl hydroxylase; Prolyl Hydroxylases - metabolism; Prolyl-Hydroxylase Inhibitors - therapeutic use; Protein Isoforms; Rheumatology; colitis; prolyl hydroxylases; inflammatory bowel disease; disease activity index

Hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitors are shown to be protective in several models of inflammatory bowel disease (IBD). However, these non-selective inhibitors are known to inhibit all the three isoforms of PHD, i.e. PHD-1, PHD-2 and PHD-3. In the present report, we inve...